JP2003513935A - マイコプラズマ・ボビスに対するワクチンおよび使用方法 - Google Patents
マイコプラズマ・ボビスに対するワクチンおよび使用方法Info
- Publication number
- JP2003513935A JP2003513935A JP2001536186A JP2001536186A JP2003513935A JP 2003513935 A JP2003513935 A JP 2003513935A JP 2001536186 A JP2001536186 A JP 2001536186A JP 2001536186 A JP2001536186 A JP 2001536186A JP 2003513935 A JP2003513935 A JP 2003513935A
- Authority
- JP
- Japan
- Prior art keywords
- mycoplasma bovis
- biotype
- vaccine
- mycoplasma
- inactivated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001138504 Mycoplasma bovis Species 0.000 title claims abstract description 154
- 229960005486 vaccine Drugs 0.000 title claims abstract description 94
- 238000000034 method Methods 0.000 title claims abstract description 28
- 241000283690 Bos taurus Species 0.000 claims abstract description 49
- 241001465754 Metazoa Species 0.000 claims abstract description 49
- 230000002238 attenuated effect Effects 0.000 claims abstract description 32
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 230000001681 protective effect Effects 0.000 claims abstract description 8
- 239000002671 adjuvant Substances 0.000 claims description 21
- 230000028993 immune response Effects 0.000 claims description 13
- 230000002163 immunogen Effects 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 230000003053 immunization Effects 0.000 claims description 5
- 230000000415 inactivating effect Effects 0.000 claims description 4
- 239000000427 antigen Substances 0.000 abstract description 20
- 108091007433 antigens Proteins 0.000 abstract description 20
- 102000036639 antigens Human genes 0.000 abstract description 20
- 208000015181 infectious disease Diseases 0.000 abstract description 20
- 208000004396 mastitis Diseases 0.000 abstract description 14
- 235000013336 milk Nutrition 0.000 abstract description 11
- 239000008267 milk Substances 0.000 abstract description 11
- 210000004080 milk Anatomy 0.000 abstract description 11
- 239000000203 mixture Substances 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 244000052769 pathogen Species 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 5
- 241000894007 species Species 0.000 abstract description 4
- 230000002458 infectious effect Effects 0.000 abstract description 3
- 230000000241 respiratory effect Effects 0.000 abstract description 3
- 230000004584 weight gain Effects 0.000 abstract description 3
- 235000019786 weight gain Nutrition 0.000 abstract description 3
- 206010060968 Arthritis infective Diseases 0.000 abstract description 2
- 206010033078 Otitis media Diseases 0.000 abstract description 2
- 206010035664 Pneumonia Diseases 0.000 abstract description 2
- 208000022760 infectious otitis media Diseases 0.000 abstract description 2
- 206010023332 keratitis Diseases 0.000 abstract description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 abstract description 2
- 230000009851 immunogenic response Effects 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 description 31
- 241000204031 Mycoplasma Species 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 20
- 244000309466 calf Species 0.000 description 14
- 244000144980 herd Species 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 244000005700 microbiome Species 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000204003 Mycoplasmatales Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 229960000380 propiolactone Drugs 0.000 description 6
- 241001430197 Mollicutes Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 235000013365 dairy product Nutrition 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 229940031551 inactivated vaccine Drugs 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 231100000065 noncytotoxic Toxicity 0.000 description 4
- 230000002020 noncytotoxic effect Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 238000009021 pre-vaccination Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 229940031567 attenuated vaccine Drugs 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000013020 final formulation Substances 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000006651 lactation Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000003771 C cell Anatomy 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical group [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000013048 microbiological method Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241000203022 Acholeplasma laidlawii Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000031462 Bovine Mastitis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000606831 Histophilus somni Species 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000191276 Mycoplasma alkalescens Species 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- XOYXESIZZFUVRD-UVSAJTFZSA-M acemannan Chemical compound CC(=O)O[C@@H]1[C@H](O)[C@@H](OC)O[C@H](CO)[C@H]1O[C@@H]1[C@@H](O)[C@@H](OC(C)=O)[C@H](O[C@@H]2[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O[C@@H]4[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]5[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]6[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]7[C@H]([C@@H](OC(C)=O)[C@H](OC)[C@@H](CO)O7)O)[C@@H](CO)O6)O)[C@H](O5)C([O-])=O)O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H](CO)O2)O)[C@@H](CO)O1 XOYXESIZZFUVRD-UVSAJTFZSA-M 0.000 description 1
- 229960005327 acemannan Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940037642 autologous vaccine Drugs 0.000 description 1
- 229950010555 avridine Drugs 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229960005191 ferric oxide Drugs 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000018934 joint symptom Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 108010009004 proteose-peptone Proteins 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012770 revaccination Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16428699P | 1999-11-08 | 1999-11-08 | |
| US60/164,286 | 1999-11-08 | ||
| PCT/US2000/042000 WO2001034189A2 (en) | 1999-11-08 | 2000-11-08 | Vaccines for mycoplasma bovis and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003513935A true JP2003513935A (ja) | 2003-04-15 |
| JP2003513935A5 JP2003513935A5 (enExample) | 2007-12-27 |
Family
ID=22593810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001536186A Pending JP2003513935A (ja) | 1999-11-08 | 2000-11-08 | マイコプラズマ・ボビスに対するワクチンおよび使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US7943153B1 (enExample) |
| EP (1) | EP1229929A2 (enExample) |
| JP (1) | JP2003513935A (enExample) |
| AU (1) | AU782508B2 (enExample) |
| BR (1) | BR0015398A (enExample) |
| CA (1) | CA2390613A1 (enExample) |
| IL (1) | IL149471A0 (enExample) |
| MX (1) | MXPA02004627A (enExample) |
| WO (1) | WO2001034189A2 (enExample) |
| ZA (1) | ZA200203622B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012507537A (ja) * | 2008-10-31 | 2012-03-29 | ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド | マイコプラズマ・ボビスの抗原を含む種々の抗原の多価ワクチン組成物における使用 |
| KR20180074804A (ko) | 2009-06-04 | 2018-07-03 | 고쿠리츠칸센쇼켄쿠죠 | 마이코플라즈마 감염증용 백신 |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2390613A1 (en) * | 1999-11-08 | 2001-05-17 | Biomune | Vaccines for mycoplasma bovis and methods of use |
| GB0110851D0 (en) * | 2001-05-03 | 2001-06-27 | Mini Agriculture & Fisheries | Vaccine |
| US20030147914A1 (en) * | 2001-07-02 | 2003-08-07 | Pfizer Inc. | Mycoplasma bovis vaccine and methods of reducing pneumonia in animals |
| EP1420636A2 (en) * | 2001-08-28 | 2004-05-26 | Pfizer Products Inc. | Mycoplasma bovis challenge model, methods for administering m. bovis and methods for inducing pneumonic lung lesions |
| WO2008030619A2 (en) * | 2006-09-07 | 2008-03-13 | Boehringer Ingelheim Vetmedica, Inc. | Pcr-based genotyping |
| CL2008003202A1 (es) | 2007-10-29 | 2009-11-27 | Boehringer Ingelheim Vetmedica Inc | Composicion inmunogenica que comprende bacterias vivas de mycoplasma bovis atenuada avirulenta. |
| ME01000B (me) * | 2007-11-06 | 2012-10-20 | Zoetis Services Llc | Živa vakcina avirulentne mycoplasma hyopneumoniae sa adjuvansom |
| EP2163239A1 (de) * | 2008-05-27 | 2010-03-17 | Qiagen GmbH | Produkte, die Biopartikel enthalten, Verfahren zu ihrer Herstellung |
| NZ589981A (en) * | 2008-07-03 | 2012-11-30 | Univ Iowa State Res Found Inc | Cattle vaccines comprising a disrupted M. bovis bacterium |
| UY32570A (es) * | 2009-04-24 | 2010-11-30 | Boehringer Ingelheim Vetmed | Vacuna viva modificada de mycoplasma bovis mejorada |
| EP2485764A4 (en) | 2009-10-09 | 2014-01-29 | Childrens Medical Center | SELECTIVELY DISCONNECTED FULL CELL VACCINE |
| WO2012041635A1 (en) * | 2010-09-29 | 2012-04-05 | Universite De Liege | Combination of an agonistic anti-cd40 monoclonal antibody or a cd40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis |
| US9052315B2 (en) | 2012-05-09 | 2015-06-09 | Advanced Animal Diagnostics, Inc. | Rapid detection of analytes in liquid samples |
| US10359614B2 (en) | 2012-07-03 | 2019-07-23 | Advanced Animal Diagnostics, Inc. | Diagnostic apparatus |
| US11369671B2 (en) | 2012-09-10 | 2022-06-28 | Galenbio, Inc. | Vaccine to prevent mycoplasmal infections in waterfowl |
| US9797893B2 (en) | 2013-05-09 | 2017-10-24 | Advanced Animal Diagnostics, Inc. | Rapid detection of analytes in liquid samples |
| CN108135989B (zh) | 2015-08-14 | 2022-08-09 | 硕腾服务有限责任公司 | 牛支原体组合物 |
| CN110338138B (zh) * | 2019-06-19 | 2021-04-06 | 山东省农业科学院奶牛研究中心 | 一种牛支原体感染豚鼠的动物模型构建方法及其应用 |
| CN113040094B (zh) * | 2021-03-18 | 2022-06-21 | 中国农业大学 | 一种牛支原体性小鼠乳腺炎模型的构建方法及其应用 |
| CN116751723A (zh) * | 2023-07-24 | 2023-09-15 | 吉林农业大学 | 一种牛支原体菌株及其灭活疫苗和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3164143D1 (en) | 1980-07-01 | 1984-07-19 | Nat Res Dev | Production of viral antigens |
| US4425330A (en) * | 1981-05-20 | 1984-01-10 | Cornell Research Foundation, Inc. | Bovine mastitis vaccine and method for detecting efficacy thereof |
| US4517394A (en) * | 1983-07-05 | 1985-05-14 | W. R. Grace & Co. | Preparation of nitro compounds by vapor phase nitration of carboxylic acids |
| US4981684A (en) | 1989-10-24 | 1991-01-01 | Coopers Animal Health Limited | Formation of adjuvant complexes |
| US5178860A (en) | 1989-09-01 | 1993-01-12 | Coopers Animal Health Limited | Adjuvant complexes and vaccine made therefrom |
| US5565205A (en) | 1990-08-16 | 1996-10-15 | Solvay Animal Health, Inc. | Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof |
| CA2057946A1 (en) * | 1990-12-20 | 1992-06-21 | Michael M. Thackeray | Electrochemical cell |
| US5316875A (en) * | 1991-07-19 | 1994-05-31 | Matsushita Electric Industrial Co., Ltd. | Secondary battery with nonaqueous electrolyte and method of manufacturing same |
| US5338543A (en) | 1992-02-27 | 1994-08-16 | Ambico, Inc. | Thimerosal inactivated mycoplasma hyopneumoniae vaccine |
| US5585098A (en) | 1993-11-23 | 1996-12-17 | Ovimmune, Inc. | Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants |
| DE69528450T2 (de) * | 1994-02-18 | 2003-01-23 | Solidose, L.L.C. | Impfung von tieren mit getrockneten pelletierten biologischen materialien |
| JP3702353B2 (ja) * | 1996-05-24 | 2005-10-05 | 日本電池株式会社 | リチウム電池用正極活物質の製造方法およびリチウム電池 |
| CA2390613A1 (en) * | 1999-11-08 | 2001-05-17 | Biomune | Vaccines for mycoplasma bovis and methods of use |
| DE29921392U1 (de) | 1999-12-06 | 2000-03-16 | Dr. Felgenträger & Co. Öko-Chem. und Pharma GmbH, 06862 Rodleben | Mykoplasma-bovis-Kombinations-Vakzine für Rinder |
| US6680143B2 (en) * | 2000-06-22 | 2004-01-20 | The University Of Chicago | Lithium metal oxide electrodes for lithium cells and batteries |
| US6677082B2 (en) * | 2000-06-22 | 2004-01-13 | The University Of Chicago | Lithium metal oxide electrodes for lithium cells and batteries |
| JP3500424B2 (ja) * | 2000-08-31 | 2004-02-23 | 独立行政法人産業技術総合研究所 | 単相リチウムフェライト系複合酸化物 |
| US6548069B2 (en) | 2001-02-03 | 2003-04-15 | Hmv Associates, Inc. | Multivalent Mycoplasma bacterin |
-
2000
- 2000-11-08 CA CA002390613A patent/CA2390613A1/en not_active Abandoned
- 2000-11-08 MX MXPA02004627A patent/MXPA02004627A/es not_active Application Discontinuation
- 2000-11-08 US US09/708,352 patent/US7943153B1/en not_active Expired - Fee Related
- 2000-11-08 JP JP2001536186A patent/JP2003513935A/ja active Pending
- 2000-11-08 IL IL14947100A patent/IL149471A0/xx unknown
- 2000-11-08 BR BR0015398-2A patent/BR0015398A/pt not_active Application Discontinuation
- 2000-11-08 EP EP00989763A patent/EP1229929A2/en not_active Withdrawn
- 2000-11-08 AU AU26225/01A patent/AU782508B2/en not_active Ceased
- 2000-11-08 WO PCT/US2000/042000 patent/WO2001034189A2/en not_active Ceased
-
2002
- 2002-05-07 ZA ZA200203622A patent/ZA200203622B/en unknown
-
2003
- 2003-12-01 US US10/726,029 patent/US7429389B2/en not_active Expired - Fee Related
-
2004
- 2004-04-14 US US10/825,391 patent/US7416734B2/en not_active Expired - Fee Related
-
2006
- 2006-07-18 US US11/489,147 patent/US20070077260A1/en not_active Abandoned
-
2007
- 2007-10-31 US US11/982,082 patent/US20090263427A1/en not_active Abandoned
- 2007-10-31 US US11/982,265 patent/US20080226671A1/en not_active Abandoned
- 2007-10-31 US US11/982,079 patent/US20090220550A1/en not_active Abandoned
Non-Patent Citations (5)
| Title |
|---|
| JPN5002020469, ＢＯＯＴＨＢＹ Ｊ Ｔ, ＣＡＮＡＤＩＡＮ ＪＯＵＲＮＡＬ ＯＦ ＶＥＴＥＲＩＮＡＲＹ ＲＥＳＥＡＲＣＨ, 198807, Ｖ５２Ｎ３, Ｐ３５５−３５９ * |
| JPN5002020470, ＨＯＷＡＲＤ Ｃ Ｊ, ＲＥＳＥＡＲＣＨ ＩＮ ＶＥＴＥＲＩＮＡＲＹ ＳＣＩＥＮＣＥ, 1979, Ｖ２８Ｎ２, Ｐ２４２−２４９ * |
| JPN7010003154, Ｖｅｔｅｒｉｎａｒｙ Ｍｉｃｒｏｂｉｏｌｏｇｙ, 1980, ５, ｐ．１１３−１２２ * |
| JPN7010003155, Ｖｅｔｅｒｉｎａｒｙ Ｒｅｃｏｒｄ, 1987, １２１, ｐ．３７２−３７６ * |
| JPN7010003156, Ｒ． Ｒｏｓｅｎｂｕｓｃｈ, Ｐｒｏｃ． １２ｔｈ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｏｒｇａｎｉｓａｔｉｏｎ ｏｆ Ｍｙｃｏｐｌａｓｍｏｌｏｇｙ Ｃｏｎｆｅｒｅｎｃｅ, 1998, ｐ．１８５ * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012507537A (ja) * | 2008-10-31 | 2012-03-29 | ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド | マイコプラズマ・ボビスの抗原を含む種々の抗原の多価ワクチン組成物における使用 |
| KR20180074804A (ko) | 2009-06-04 | 2018-07-03 | 고쿠리츠칸센쇼켄쿠죠 | 마이코플라즈마 감염증용 백신 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR0015398A (pt) | 2002-06-25 |
| AU782508B2 (en) | 2005-08-04 |
| US20050118200A1 (en) | 2005-06-02 |
| US7416734B2 (en) | 2008-08-26 |
| WO2001034189A3 (en) | 2001-12-27 |
| AU2622501A (en) | 2001-06-06 |
| US20050053627A1 (en) | 2005-03-10 |
| CA2390613A1 (en) | 2001-05-17 |
| MXPA02004627A (es) | 2004-02-18 |
| IL149471A0 (en) | 2002-11-10 |
| WO2001034189A2 (en) | 2001-05-17 |
| US20090263427A1 (en) | 2009-10-22 |
| ZA200203622B (en) | 2003-07-30 |
| EP1229929A2 (en) | 2002-08-14 |
| US20070077260A1 (en) | 2007-04-05 |
| US20080226671A1 (en) | 2008-09-18 |
| US20080069842A9 (en) | 2008-03-20 |
| US20090220550A1 (en) | 2009-09-03 |
| US7429389B2 (en) | 2008-09-30 |
| US7943153B1 (en) | 2011-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090263427A1 (en) | Vaccines for mycoplasma bovis and methods of use | |
| EP2561063B1 (en) | A vaccine comprising inactivated cells of haemophilus parasuis bacteria of serotype 5 | |
| SK15792003A3 (sk) | Použitie Mycoplasma hyopneumoniae na výrobu liečiva | |
| JP5651677B2 (ja) | 各種血清型のブタ連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｓｕｉｓ）細菌から防御するためのワクチン | |
| CN101827605B (zh) | 牛支原体疫苗 | |
| US6585981B1 (en) | Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae | |
| JP3178720B2 (ja) | パスツレラ・ムルトシダのトキソイドワクチン | |
| UA121097C2 (uk) | Імуногенна композиція, що містить антигени мікоплазм | |
| RU2043771C1 (ru) | Вакцина против эшерихиоза животных | |
| KR101210082B1 (ko) | 돼지 다발성 장막염 예방용 백신 조성물 및 그 제조방법 | |
| US8563005B2 (en) | Actinobacillus suis antigens | |
| CN115243715B (en) | Vaccine protecting against serotype 9, sequence 16 streptococcus suis | |
| JP2020522471A (ja) | クロストリジウム類毒素を含むワクチン | |
| Walker | Bacterial vaccines | |
| CN115243715A (zh) | 保护以对抗血清型9、序列型16的猪链球菌的疫苗 | |
| Smith | The Use of live cultures of Pasteurella haemolytica Pasteurella multocida to immunize cattle against bovine respiratory disease | |
| Farley | Studies on shipping fever | |
| HK1134900B (en) | One dose vaccination with (1) mycoplasma hyopneumoniae (/1) | |
| AU2001277207A2 (en) | Temperature-sensitive live vaccine for mycoplasma hyopneumoniae |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071107 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071107 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101012 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110112 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110119 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110214 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110221 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110705 |